Analysis of real-world data demonstrating the efficacy of current management of polycythaemia vera in attaining and maintaining therapeutic haematocrit

Frances D. Buckley, Claire Arnold, Dawn Brass, Mark Catherwood, Mary Frances McMullin (Lead / Corresponding author)

Research output: Contribution to journalArticlepeer-review

14 Downloads (Pure)

Abstract

Background: Polycythaemia vera (PV) is a Philadelphia-negative myeloproliferative neoplasm, typically driven by acquired JAK2 mutation and characterised by elevated red cell mass and increased risk of thrombotic events. Patients are managed with phlebotomy to maintain haematocrit (Hct) < 0.45, and patients stratified as 'high risk' for thrombosis are additionally treated with cytoreductive agents to attain this target.

Study: This analysis of newly diagnosed JAK2 mutant PV patients (n = 50) over 2 years aimed to determine how effectively patients attained and maintained target Hct according to recommended practice.

Conclusions: We found that patients spent the majority of time in target Hct range. Findings are supportive of current management guidelines.

Original languageEnglish
Pages (from-to)833-836
Number of pages4
JournalIrish Journal of Medical Science
Volume193
Early online date8 Sept 2023
DOIs
Publication statusPublished - Apr 2024

Keywords

  • Haematology
  • Myeloproliferative neoplasms
  • Polycythaemia

Fingerprint

Dive into the research topics of 'Analysis of real-world data demonstrating the efficacy of current management of polycythaemia vera in attaining and maintaining therapeutic haematocrit'. Together they form a unique fingerprint.

Cite this